Cassava sciences completes patient enrollment for pivotal phase 3 clinical trial of oral simufilam in alzheimer's disease

Austin, texas, oct. 02, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a biotechnology company, today announced the completion of patient enrollment in a pivotal phase 3 clinical trial. eight hundred four (804) alzheimer's patients are enrolled in this 12-month trial. a second phase 3 clinical trial with a target enrollment of approximately 1,100 patients is expected to complete patient enrollment in q4 2023. both on-going phase 3 clinical trials are evaluating the safety and efficacy of oral simufilam in patients with alzheimer's disease dementia.
SAVA Ratings Summary
SAVA Quant Ranking